PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet, respectively -- -- Company ...

Inozyme recently featured new clinical insights and hosted an educational symposium at the Joint Congress of the European ...

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type ...

Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM)Manage ...

ATH-1105 is the Company's novel, orally available, brain-penetrant, next-generation small molecule drug candidate designed to ...

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going ...

Minghui Pharma enters strategic partnership and licensing pact with Qilu Pharma to develop B7-H3 ADC in Greater China: Shanghai Monday, May 12, 2025, 12:00 Hrs [IST] Minghui Pharm ...

Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire ...

Q1 2025 Earnings Call Transcript May 12, 2025 Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.83, ...

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...